Clinical
Trials

We conduct many clinical trials that evaluate the effectiveness and safety of emerging technologies, medicines, treatments and therapies. Our patients benefit by having access to some of the latest approaches and treatments for serious or challenging medical conditions—without having to leave the community. All of our studies are overseen by an Institutional Review Board (IRB) to ensure the highest standards of human subjects protection are always followed.

Open Clinical Trials

Creon Study

Creon (Pancrelipase) Therapy for Subjects With Exocrine Pancreatic Insufficiency (EPI) Due to Pancreatic Cancer: A Double-blind, Randomized, Parallel Design with 2 Dose Cohorts of Pancrelipase in Resected Pancreatic Cancer Subjects and an Open-label Single Dose Cohort in Non-resected Pancreatic Cancer Subjects

Principal Investigator: Dr. Malcolm Bilimoria

Study Overview: This is a study in participants with Exocrine Pancreatic Insufficiency (EPI) due to pancreatic cancer that has been resected. This study will include resected participants who are post pancreatic cancer surgery, and an exploratory cohort in non-resected participants.

For more information, please click on the following link which will take you to the study site on clinicaltrials.gov:

Metformin Study

A Randomized Placebo Controlled Phase II Trial of Metformin In Conjunction with Chemotherapy Followed by Metformin Maintenance Therapy in Advanced Stage Ovarian, Fallopian Tube and Primary Peritoneal Cancer

Principal Investigator: Dr. S. Diane Yamada

Study Overview: This randomized phase II trial studies how well metformin hydrochloride and combination chemotherapy works in treating patients with stage III-IV ovarian, fallopian tube, or primary peritoneal cancer. Drugs used in chemotherapy, such as carboplatin, paclitaxel and docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Metformin hydrochloride may help carboplatin, paclitaxel and docetaxel work better by making tumor cells more sensitive to the drugs.

For more information, please click on the following link which will take you to the study site on clinicaltrials.gov:

Institutional Review Board (IRB)

Our IRB is a multidisciplinary team of medical professionals and community members that review all applicable research performed at the hospital from the perspective of human subjects protection.

Our mission is to protect the rights, privacy and safety of patients who participate in research at the hospital. We achieve this by ensuring that all protocols approved are of the highest level of integrity as we all comply with federal government regulations and guidelines.

IRB Organization and FederalWide Assurance

Both the IRB and its board are registered in the Office for Human Research Protections (OHRP) Database. To confirm, you can use the following information:

  • NCH’s IRB Office Organization number is IORG0002660
  • NCH’s IRB Committee #1’s FWA number is FWA00004329

We offer additional information about becoming an investigator or co-investigator in a clinical trial at NCH.

NCH Policies and Procedures which govern clinical research are available upon request by contacting the NCH IRB Office.

© 2020 Northwest Community Healthcare. All rights reserved.